Safety and clinical effects of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson’s disease (PD): 81 to 130 weeks follow-up
Objective: To follow the clinical status of 4 PD patients transplanted with NTCELL out to 81-130 weeks. Background: NTCELL comprises neonatal porcine choroid plexus cells…Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial
Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study
Objective: To analyze the long-term retrospective data of patients treated with Levodopa/carbidopa intestinal gel infusion (LCIG) and subthalamic nucleus deep brain stimulation (STN-DBS) in two…Improving provision of Parkinson’s disease exercise classes
Objective: (1) To identify common barriers and limitations related to the delivery of Parkinson's disease (PD) exercise classes; (2) To recommend interventions with widespread applicability…Auditory cues during obstacle crossing increase gait asymmetry in neurologically health individuals but not in people with Parkinson’s disease
Objective: To investigate the influence of auditory cue on gait asymmetry in an environment unobstructed and with obstacle in people with Parkinson's disease (PD) and…Utilization and longitudinal impact of amantadine use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry
Objective: To evaluate baseline predictors and longitudinal impact of amantadine use in Parkinson's disease (PD). Background: There is preclinical data that amantadine has neuroprotective properties,…Status of NPF-QII after six years: Updates to the dataset
Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…Neural plasticity and freezing of gait: Stepping through the FoG
Objective: 1) To determine the efficacy of our cognitively challenging Agility Boot Camp (ABC-C) rehabilitation intervention and 2) to evaluate neural mechanisms and plasticity within…Classification and recommendation of nonpharmacological therapies for Parkinson’s disease
Objective: A multidisciplinary specialized treatment including physiotherapy, speech and language therapy, occupational therapy (OT) associated to the ideal pharmacological treatment and surgical is recommended to…Development of a human neuroblastoma model of pantothenate kinase-associated neurodegeneration
Objective: To establish a stable human neuronal model defective in PanK2. Background: Pantothenate Kinase-Associated Neurodegeneration (PKAN), is caused by mutations in PANK2, which encodes one…
- « Previous Page
- 1
- …
- 153
- 154
- 155
- 156
- 157
- …
- 207
- Next Page »